Stock Analysis

InMode First Quarter 2024 Earnings: Misses Expectations

NasdaqGS:INMD
Source: Shutterstock

InMode (NASDAQ:INMD) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$80.3m (down 24% from 1Q 2023).
  • Net income: US$23.7m (down 42% from 1Q 2023).
  • Profit margin: 30% (down from 38% in 1Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: US$0.28 (down from US$0.49 in 1Q 2023).
earnings-and-revenue-growth
NasdaqGS:INMD Earnings and Revenue Growth May 3rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

InMode Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 2.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of InMode's balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're helping make it simple.

Find out whether InMode is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:INMD

InMode

Designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally.

Flawless balance sheet and undervalued.